
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences Inc. is positioned for significant growth due to its focus on developing CGT9486, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation responsible for systemic mastocytosis. Positive data emerging from multiple clinical trials, such as APEX, PEAK, and SUMMIT, strengthens the potential of bezuclastinib in treating various malignancies, indicating a robust pipeline for future revenue generation. The year 2025 is anticipated to be pivotal for Cogent, possibly increasing its attractiveness as a merger and acquisition target within the biotechnology sector.
Bears say
Cogent Biosciences Inc. is projected to incur a full-year net loss of $2.28 per share in 2025, indicating potential financial distress for the company. This negative outlook is compounded by significant risks, including the possibility of negative clinical data from key drug candidates, slower development timelines, and potential failures in obtaining necessary regulatory approvals. There is also concern regarding long-term dilution risks and lower-than-expected commercial success, which could further undermine investor confidence and financial performance.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares